AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Annovis Bio, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Annovis Bio, Inc. furnished a Current Report on Form 8-K stating that on August 12, 2025 the company issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing a corporate update. The filing indicates the press release is included as Exhibit 99.1 and also includes the Cover Page Interactive Data File as Exhibit 104. The registrant is identified as an emerging growth company and has elected not to use the extended transition period for new or revised accounting standards.

The 8-K text itself does not present the numerical results or additional operational details; those items are contained in the referenced press release furnished as an exhibit.

Annovis Bio, Inc. ha presentato un Current Report sul Modulo 8‑K, indicando che il 12 agosto 2025 la società ha diffuso un comunicato stampa con i risultati finanziari relativi al secondo trimestre chiuso il 30 giugno 2025 e fornendo un aggiornamento aziendale. Il deposito segnala che il comunicato è incluso come Exhibit 99.1 e comprende inoltre il file dei Dati Interattivi della pagina di copertina come Exhibit 104. L'emittente è identificato come emerging growth company e ha scelto di non utilizzare il periodo di transizione esteso per i nuovi o rivisti principi contabili.

Il testo dell'8‑K non riporta i risultati numerici né ulteriori dettagli operativi; tali informazioni sono contenute nel comunicato citato e presentato come allegato.

Annovis Bio, Inc. presentó un Current Report en el Formulario 8‑K indicando que, el 12 de agosto de 2025, la compañía emitió un comunicado de prensa anunciando sus resultados financieros del segundo trimestre finalizado el 30 de junio de 2025 y ofreciendo una actualización corporativa. La presentación indica que el comunicado se incluye como Exhibit 99.1 y también incorpora el archivo de datos interactivos de la página de portada como Exhibit 104. El registrante está identificado como una emerging growth company y ha optado por no utilizar el período de transición ampliado para las normas contables nuevas o revisadas.

El texto del 8‑K en sí no presenta los resultados numéricos ni detalles operativos adicionales; esos elementos se encuentran en el comunicado referenciado y suministrado como anexo.

Annovis Bio, Inc.ëŠ� Form 8‑Kì� Current Reportë¥� 제출하여 2025ë…� 8ì›� 12ì� ìž� ë³´ë„ìžë£Œë¥� 통해 2025ë…� 6ì›� 30ì¼ë¡œ 종료ë� 2분기 재무 실ì ì� 발표하고 회사 ì—…ë°ì´íЏë¥� 제공했다ê³� ë°í˜”습니ë‹�. 제출서ì—ëŠ� 해당 ë³´ë„ìžë£Œê°€ Exhibit 99.1ë¡� í¬í•¨ë˜ì–´ 있고 표지 페ì´ì§€ì� 대화형 ë°ì´í„� 파ì¼ì� Exhibit 104ë¡� í¬í•¨ë˜ì–´ 있다ê³� 기재ë˜ì–´ 있습니다. 등ë¡íšŒì‚¬ëŠ� emerging growth company(ì‹ í¥ ì„±ìž¥ 기업)ë¡� 분류ë˜ë©° 새로ìš� ë˜ëŠ” 개정ë� 회계 기준ì—� 대í•� 연장 전환 기간ì� 사용하지 않기ë¡� ì„ íƒí–ˆìŠµë‹ˆë‹¤.

8‑K 본문ì—는 수치 ê²°ê³¼ë‚� 추가 ìš´ì˜ ì„¸ë¶€ì‚¬í•­ì� 기재ë˜ì–´ 있지 않으ë©�, 해당 ë‚´ìš©ì€ ì²¨ë¶€ë� ë³´ë„ìžë£Œì—� í¬í•¨ë˜ì–´ 있습니다.

Annovis Bio, Inc. a déposé un Current Report sur le Form 8‑K indiquant que, le 12 août 2025, la société a publié un communiqué annonçant ses résultats financiers pour le deuxième trimestre clos le 30 juin 2025 et fournissant une mise à jour d'entreprise. Le dépôt précise que le communiqué est inclus en tant que Exhibit 99.1 et comprend également le fichier de données interactives de la page de couverture en tant qu'Exhibit 104. L'émetteur est identifié comme une emerging growth company et a choisi de ne pas utiliser la période de transition prolongée pour les normes comptables nouvelles ou révisées.

Le texte de l'8‑K ne présente pas lui‑même les résultats chiffrés ni d'autres détails opérationnels ; ces éléments figurent dans le communiqué référencé et fourni en annexe.

Annovis Bio, Inc. reichte einen Current Report auf Form 8‑K ein und gab an, dass das Unternehmen am 12. August 2025 eine Pressemitteilung veröffentlicht hat, in der es seine Finanzergebnisse für das zweite Quartal zum 30. Juni 2025 bekanntgab und ein Unternehmensupdate bereitstellte. Die Einreichung weist darauf hin, dass die Pressemitteilung als Exhibit 99.1 beigefügt ist und ferner die interaktiven Deckblattdaten als Exhibit 104 enthält. Der Registrant ist als emerging growth company eingestuft und hat darauf verzichtet, den verlängerten Übergangszeitraum für neue oder überarbeitete Rechnungslegungsstandards zu nutzen.

Der Text des 8‑K selbst enthält keine Zahlen oder zusätzlichen operativen Angaben; diese Informationen sind in der als Anlage beigefügten Pressemitteilung enthalten.

Positive
  • None.
Negative
  • None.

Insights

Routine disclosure furnishing a press release; no financial figures appear in the 8-K text, so material impact is unclear from this filing alone.

The Form 8-K notifies investors that a press release with the company’s second-quarter 2025 financial results and a corporate update was issued and furnished as Exhibit 99.1. Because the filing does not reproduce the financial statements or key metrics, this document by itself provides limited actionable data for valuation or performance analysis. Investors and analysts must review the attached press release for revenues, earnings, cash position, guidance, or other metrics to assess material impact.

Standard Section 2.02 disclosure; filing indicates timely public release via Exhibit 99.1 and notes emerging growth company status.

The 8-K reflects a procedural furnishing of a press release rather than a governance change or transaction. It confirms the company’s status as an emerging growth company and its election not to use the extended transition period for new accounting standards, which are governance-disclosure items of record. No executive departures, related-party transactions, or material governance actions are disclosed in this filing.

Annovis Bio, Inc. ha presentato un Current Report sul Modulo 8‑K, indicando che il 12 agosto 2025 la società ha diffuso un comunicato stampa con i risultati finanziari relativi al secondo trimestre chiuso il 30 giugno 2025 e fornendo un aggiornamento aziendale. Il deposito segnala che il comunicato è incluso come Exhibit 99.1 e comprende inoltre il file dei Dati Interattivi della pagina di copertina come Exhibit 104. L'emittente è identificato come emerging growth company e ha scelto di non utilizzare il periodo di transizione esteso per i nuovi o rivisti principi contabili.

Il testo dell'8‑K non riporta i risultati numerici né ulteriori dettagli operativi; tali informazioni sono contenute nel comunicato citato e presentato come allegato.

Annovis Bio, Inc. presentó un Current Report en el Formulario 8‑K indicando que, el 12 de agosto de 2025, la compañía emitió un comunicado de prensa anunciando sus resultados financieros del segundo trimestre finalizado el 30 de junio de 2025 y ofreciendo una actualización corporativa. La presentación indica que el comunicado se incluye como Exhibit 99.1 y también incorpora el archivo de datos interactivos de la página de portada como Exhibit 104. El registrante está identificado como una emerging growth company y ha optado por no utilizar el período de transición ampliado para las normas contables nuevas o revisadas.

El texto del 8‑K en sí no presenta los resultados numéricos ni detalles operativos adicionales; esos elementos se encuentran en el comunicado referenciado y suministrado como anexo.

Annovis Bio, Inc.ëŠ� Form 8‑Kì� Current Reportë¥� 제출하여 2025ë…� 8ì›� 12ì� ìž� ë³´ë„ìžë£Œë¥� 통해 2025ë…� 6ì›� 30ì¼ë¡œ 종료ë� 2분기 재무 실ì ì� 발표하고 회사 ì—…ë°ì´íЏë¥� 제공했다ê³� ë°í˜”습니ë‹�. 제출서ì—ëŠ� 해당 ë³´ë„ìžë£Œê°€ Exhibit 99.1ë¡� í¬í•¨ë˜ì–´ 있고 표지 페ì´ì§€ì� 대화형 ë°ì´í„� 파ì¼ì� Exhibit 104ë¡� í¬í•¨ë˜ì–´ 있다ê³� 기재ë˜ì–´ 있습니다. 등ë¡íšŒì‚¬ëŠ� emerging growth company(ì‹ í¥ ì„±ìž¥ 기업)ë¡� 분류ë˜ë©° 새로ìš� ë˜ëŠ” 개정ë� 회계 기준ì—� 대í•� 연장 전환 기간ì� 사용하지 않기ë¡� ì„ íƒí–ˆìŠµë‹ˆë‹¤.

8‑K 본문ì—는 수치 ê²°ê³¼ë‚� 추가 ìš´ì˜ ì„¸ë¶€ì‚¬í•­ì� 기재ë˜ì–´ 있지 않으ë©�, 해당 ë‚´ìš©ì€ ì²¨ë¶€ë� ë³´ë„ìžë£Œì—� í¬í•¨ë˜ì–´ 있습니다.

Annovis Bio, Inc. a déposé un Current Report sur le Form 8‑K indiquant que, le 12 août 2025, la société a publié un communiqué annonçant ses résultats financiers pour le deuxième trimestre clos le 30 juin 2025 et fournissant une mise à jour d'entreprise. Le dépôt précise que le communiqué est inclus en tant que Exhibit 99.1 et comprend également le fichier de données interactives de la page de couverture en tant qu'Exhibit 104. L'émetteur est identifié comme une emerging growth company et a choisi de ne pas utiliser la période de transition prolongée pour les normes comptables nouvelles ou révisées.

Le texte de l'8‑K ne présente pas lui‑même les résultats chiffrés ni d'autres détails opérationnels ; ces éléments figurent dans le communiqué référencé et fourni en annexe.

Annovis Bio, Inc. reichte einen Current Report auf Form 8‑K ein und gab an, dass das Unternehmen am 12. August 2025 eine Pressemitteilung veröffentlicht hat, in der es seine Finanzergebnisse für das zweite Quartal zum 30. Juni 2025 bekanntgab und ein Unternehmensupdate bereitstellte. Die Einreichung weist darauf hin, dass die Pressemitteilung als Exhibit 99.1 beigefügt ist und ferner die interaktiven Deckblattdaten als Exhibit 104 enthält. Der Registrant ist als emerging growth company eingestuft und hat darauf verzichtet, den verlängerten Übergangszeitraum für neue oder überarbeitete Rechnungslegungsstandards zu nutzen.

Der Text des 8‑K selbst enthält keine Zahlen oder zusätzlichen operativen Angaben; diese Informationen sind in der als Anlage beigefügten Pressemitteilung enthalten.

false 0001477845 0001477845 2025-08-12 2025-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): August 12, 2025

 

 

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter) 

 

 

Delaware 001-39202 26-2540421
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 

101 Lindenwood Drive, Suite 225
Malvern
, PA 19355

(Address of Principal Executive Offices, and Zip Code)

 

(484) 875-3192

Registrant’s Telephone Number, Including Area Code

 

                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share ANVS New York Stock Exchange

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 12, 2025, Annovis Bio, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
No. 
  Description
99.1   Press Release Dated August 12, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ANNOVIS BIO, INC.
   
Date: August 12, 2025 By: /s/ Maria Maccecchini
    Name: Maria Maccecchini
    Title: President and Chief Executive Officer

 

 

 

FAQ

What did Annovis Bio (ANVS) report in this 8-K?

The 8-K furnishes a press release dated August 12, 2025 that announces the company’s financial results for the second quarter ended June 30, 2025 and provides a corporate update; the press release is attached as Exhibit 99.1.

Does the Form 8-K include the company’s Q2 2025 financial figures?

No. The 8-K states a press release containing the second-quarter results was issued and is furnished as Exhibit 99.1, but the body of this Form 8-K does not present the numeric financial results.

Is Annovis Bio considered an emerging growth company in this filing?

Yes. The filing indicates Annovis Bio is an emerging growth company and that it has elected not to use the extended transition period for complying with new or revised accounting standards.

What exhibits were filed with this 8-K?

Exhibit 99.1: Press Release dated August 12, 2025; Exhibit 104: Cover Page Interactive Data File (Inline XBRL).

Who signed the 8-K for Annovis Bio (ANVS)?

Maria Maccecchini, President and Chief Executive Officer, signed the Form 8-K on behalf of the registrant.
Annovis Bio Inc

NYSE:ANVS

ANVS Rankings

ANVS Latest News

ANVS Latest SEC Filings

ANVS Stock Data

49.69M
16.62M
14.69%
16.03%
12.63%
Biotechnology
Pharmaceutical Preparations
United States
MALVERN